Key clinical point: Trough concentrations of pazopanib in approximately the 20- to 50-mcg/mL range were associated with less toxicity but a similar overall response rate, versus higher concentrations.
Major finding: The overall response rate was about 46% in patients with pazopanib concentrations in that range, and in patients with higher concentrations. One patient in the “optimal” range experienced a grade 3 or greater toxicity.
Study details: An exploratory analysis including 27 patients with renal cell carcinoma.
Disclosures: The authors reported no conflicts of interest.
Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001.
This Week's Must Reads
Must Reads in Renal Cell Carcinoma
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.